Email email@example.com to reserve your spot.
Organotypic 3D-cell-culture systems can help to gain additional information about the efficacy and toxicology of new drug candidates. Similarities to in vivo have been demonstrated by numerous publications and drug-development companies are moving towards 3D cell culture within the various steps of their development process.
This workshop aims at providing a basic review of different 3D cell-culture and microtissue-culture technologies, and at illustrating their applications in oncology and toxicology. In addition, examples of the successful use of microtissue models up to the regulatory level are given for skin applications as well as the use of 3D microtissue models in high-content screening. How Fluofarma, a CRO with a substantial
experience in the field, is doing this, will be presented during the workshop as well.
Workshop attendees will benefit from the latest insights into 3D cell-culture technologies for toxicological and efficacy studies. In addition, the workshop is a platform for scientific exchange and provides the chance to meet and network with academic and industry peers active and interested in the field.
1:30 pm – 02:15 pm 3D cell-culture technologies overview, Dr. Jens M. Kelm, Head of Product Management and Co-Founder, InSphero AG
2:15 pm – 3:00 pm microtissues in oncology, Dr. Peter Frost, CEO, Frost Lifescience
3:00 pm – 3:30 pm coffee break
3:30 pm – 4:15 pm organotypic cell models in toxicology, Jens M. Kelm
4:15 pm – 4:45 pm an in-vitro success story: Skin models, Peter Frost
4:45 pm – 5:15 pm high-content screening with microtissues at Fluofarma, Jens M. Kelm
5:15 pm networking and reception
InSphero is a Swiss-based company and a leading developer and manufacturer of ready-to-use 3D microtissues for applications in oncology and toxicology. Its patent-pending culture technology in hanging drops allows for automatic mass production of scaffold-free microtissues with an excellent size and density variability. The microtissues are delivered in a standard 96-well plate and allow for a straightforward upgrade from cell-based assays in monolayers to 3D microtissues.
Photo: Myleen Hollero